A Phase I, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Diseases and Conditions Researched

Bladder; Breast - Female; Colon; Lung; Melanoma, skin; Other Endocrine System; Other Respiratory and Intrathoracic Organs; Other Urinary; Ovary; Rectum; Stomach

What is the purpose of this trial?

This is a Phase 1, open-label, dose-escalation trial of MSB0010718C [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications.

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: EMD Serono, Inc.
Last Updated:
Study HIC#: 1309012779